As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
11 Analysts have issued a Agenus Inc. forecast:
11 Analysts have issued a Agenus Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 102 102 |
36%
36%
|
|
Gross Profit | 101 101 |
36%
36%
|
|
EBITDA | -78 -78 |
21%
21%
|
EBIT (Operating Income) EBIT | -91 -91 |
20%
20%
|
Net Profit | -166 -166 |
26%
26%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
Head office | United States |
CEO | Garo Armen |
Employees | 316 |
Founded | 1994 |
Website | agenusbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.